km-233 km-233 km-233 is a synthetic cannabinoid drug which is a structural analog of δ8-tetrahydrocannabinol (thc), the less active but more stable isomer of the active component of cannabis. km-233 differs from δ8-thc by the pentyl side chain being replaced by a 1,1-dimethylbenzyl group. it has high binding affinity in vitro for both the cb1 and cb2 receptors, with a cb2 affinity of 0.91 nm and 13-fold selectivity over the cb1 receptor. in animal studies, it has been found to be a potential treatment for glioma, a form of brain tumor. many related analogues are known where the 1,1-dimethylbenzyl group is substituted or replaced by other groups, with a fairly well established structure-activity relationship. km-233clinical dataatc codenoneidentifiers iupac name (−)-(6ar,7,10,10ar)-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6h-dibenzopyran-1-ol cas number628263-22-9chemspider8423597chemblchembl119592comptox dashboard (epa)dtxsid50745439 chemical and physical dataformulac25h30o2molar mass362.513 g·mol−13d model (jsmol)interactive image smiles cc1=cc2(c1)c3=c(c=c(c=c3oc2(c)c)c(c)(c)c4=cc=cc=c4)o inchi inchi=1s/c25h30o2/c1-16-11-12-20-19(13-16)23-21(26)14-18(15-22(23)27-25(20,4)5)24(2,3)17-9-7-6-8-10-17/h6-11,14-15,19-20,26h,12-13h2,1-5h3/t19-,20-/m1/s1key:gzyxcxrhvalijd-wojbjxkfsa-n